α-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy

K. E. Paleologou, G. B. Irvine, Omar Ali El-Agnaf

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

There is strong evidence for the involvement of α-synuclein in the pathologies of several neurodegenerative disorders, including PD (Parkinson's disease). Development of disease appears to be linked to processes that increase the rate at which α-synuclein forms aggregates. These processes include increased protein concentration (via either increased rate of synthesis or decreased rate of degradation), and altered forms of α-synuclein (such as truncations, missense mutations, or chemical modifications by oxidative reactions). Aggregated forms of the protein are toxic to cells and one therapeutic strategy would be to reduce the rate at which aggregation occurs. To this end we have designed several peptides that reduce α-synuclein aggregation. A cell-permeable version of one such peptide was able to inhibit the DNA damage induced by Fe(II) in neuronal cells transfected with α-synuclein (A53T), a familial PD-associated mutation.

Original languageEnglish
Pages (from-to)1106-1110
Number of pages5
JournalBiochemical Society Transactions
Volume33
Issue number5
DOIs
Publication statusPublished - Nov 2005
Externally publishedYes

Fingerprint

Synucleins
Neurodegenerative diseases
Neurodegenerative Diseases
Agglomeration
Parkinson Disease
Therapeutics
Peptides
Poisons
Chemical modification
Pathology
Missense Mutation
DNA Damage
Proteins
Degradation
Mutation
DNA

Keywords

  • α-synuclein
  • β-sheet-breaker peptide
  • Amyloid
  • Fibril
  • Parkinson's disease

ASJC Scopus subject areas

  • Biochemistry

Cite this

α-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy. / Paleologou, K. E.; Irvine, G. B.; Ali El-Agnaf, Omar.

In: Biochemical Society Transactions, Vol. 33, No. 5, 11.2005, p. 1106-1110.

Research output: Contribution to journalArticle

@article{1dbfc84b0fbf4ba9b69fbc22590a5b22,
title = "α-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy",
abstract = "There is strong evidence for the involvement of α-synuclein in the pathologies of several neurodegenerative disorders, including PD (Parkinson's disease). Development of disease appears to be linked to processes that increase the rate at which α-synuclein forms aggregates. These processes include increased protein concentration (via either increased rate of synthesis or decreased rate of degradation), and altered forms of α-synuclein (such as truncations, missense mutations, or chemical modifications by oxidative reactions). Aggregated forms of the protein are toxic to cells and one therapeutic strategy would be to reduce the rate at which aggregation occurs. To this end we have designed several peptides that reduce α-synuclein aggregation. A cell-permeable version of one such peptide was able to inhibit the DNA damage induced by Fe(II) in neuronal cells transfected with α-synuclein (A53T), a familial PD-associated mutation.",
keywords = "α-synuclein, β-sheet-breaker peptide, Amyloid, Fibril, Parkinson's disease",
author = "Paleologou, {K. E.} and Irvine, {G. B.} and {Ali El-Agnaf}, Omar",
year = "2005",
month = "11",
doi = "10.1042/BST20051106",
language = "English",
volume = "33",
pages = "1106--1110",
journal = "Biochemical Society Transactions",
issn = "0300-5127",
publisher = "Portland Press Ltd.",
number = "5",

}

TY - JOUR

T1 - α-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy

AU - Paleologou, K. E.

AU - Irvine, G. B.

AU - Ali El-Agnaf, Omar

PY - 2005/11

Y1 - 2005/11

N2 - There is strong evidence for the involvement of α-synuclein in the pathologies of several neurodegenerative disorders, including PD (Parkinson's disease). Development of disease appears to be linked to processes that increase the rate at which α-synuclein forms aggregates. These processes include increased protein concentration (via either increased rate of synthesis or decreased rate of degradation), and altered forms of α-synuclein (such as truncations, missense mutations, or chemical modifications by oxidative reactions). Aggregated forms of the protein are toxic to cells and one therapeutic strategy would be to reduce the rate at which aggregation occurs. To this end we have designed several peptides that reduce α-synuclein aggregation. A cell-permeable version of one such peptide was able to inhibit the DNA damage induced by Fe(II) in neuronal cells transfected with α-synuclein (A53T), a familial PD-associated mutation.

AB - There is strong evidence for the involvement of α-synuclein in the pathologies of several neurodegenerative disorders, including PD (Parkinson's disease). Development of disease appears to be linked to processes that increase the rate at which α-synuclein forms aggregates. These processes include increased protein concentration (via either increased rate of synthesis or decreased rate of degradation), and altered forms of α-synuclein (such as truncations, missense mutations, or chemical modifications by oxidative reactions). Aggregated forms of the protein are toxic to cells and one therapeutic strategy would be to reduce the rate at which aggregation occurs. To this end we have designed several peptides that reduce α-synuclein aggregation. A cell-permeable version of one such peptide was able to inhibit the DNA damage induced by Fe(II) in neuronal cells transfected with α-synuclein (A53T), a familial PD-associated mutation.

KW - α-synuclein

KW - β-sheet-breaker peptide

KW - Amyloid

KW - Fibril

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=27844472158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27844472158&partnerID=8YFLogxK

U2 - 10.1042/BST20051106

DO - 10.1042/BST20051106

M3 - Article

C2 - 16246056

AN - SCOPUS:27844472158

VL - 33

SP - 1106

EP - 1110

JO - Biochemical Society Transactions

JF - Biochemical Society Transactions

SN - 0300-5127

IS - 5

ER -